Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- South Korean Partner to Locally Manufacture Xocova: Shionogi
December 28, 2023
- Healios, Nobelpharma Ink Basic Deal for Cell Therapy Alliance in ARDS
December 28, 2023
- Amylyx Gears Up to Bring New ALS Drug to Japan Market: Country Chief
December 27, 2023
- Eisai, Oita University Develop Wearable Sensor to Predict Brain Aβ Buildup
December 27, 2023
- iPSC-Based Parkinson’s Therapy Cleared for Investigator-Led Trial in US: Sumitomo
December 27, 2023
- Daiichi’s HER3 ADC Gets Priority Review in US for 3rd Line EGFR-Mutated NSCLC
December 26, 2023
- Mochida Files Label Expansion for Inhaled Treprost in Japan
December 26, 2023
- Sandoz to Take Over Distribution Rights to Japan’s 1st Humira Biosimilar
December 26, 2023
- Manabu Chikumoto to Helm Mitsubishi Chemical Group from April
December 25, 2023
- Rune Ejler Andersen Tapped as Japan Chief of Lundbeck
December 25, 2023
- Astellas Closes Buyout of US Prostate Cancer Drug Maker Propella
December 25, 2023
- Meiji’s Kostaive Booster Dose Non-Inferior to Pfizer COVID Jab: PIII Data
December 25, 2023
- Sawai Slapped with Biz Improvement Order over Rigged Quality Tests
December 22, 2023
- Mitsubishi Tanabe Sells Entire Stake in China JV to Local Firm
December 22, 2023
- Nippon Shinyaku’s DMD Med Snags Orphan Status in Europe
December 22, 2023
- Ono, UK DRI to Partner in Dementia Drug Discovery Research
December 21, 2023
- Maruishi Gains Japan Rights to Allay’s Postoperative Pain Relief Drug
December 21, 2023
- JCR, Alexion Tie Up to Develop Oligonucleotide Therapeutics
December 21, 2023
- JCR, Takeda Wind Up Collab on Gene Therapy Research
December 21, 2023
- Shionogi’s Novel Antibiotic Fetroja Now Available in Japan
December 21, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…